Simvastatin inhibits Staphylococcus aureus host cell invasion through modulation of isoprenoid intermediates

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 1, 2008, Pages 135-143

  Horn, Mary P ^a   Knecht, Sharmon M ^a   Rushing, Frances L ^a   Birdsong, Julie ^a   Siddall, C Parker ^a   Johnson, Charron M ^a   Abraham, Terri N ^a   Brown, Amy ^a   Volk, Catherine B ^a   Gammon, Kelly ^a   Bishop, Derron L ^b   McKillip, John L ^a   McDowell, Susan A ^a  

^a BALL STATE UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GUANOSINE TRIPHOSPHATASE; ISOPRENOID; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN CDC42; PROTEIN P85; RAC1 PROTEIN; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; SIMVASTATIN;

ACTIN FILAMENT; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL VIRULENCE; CELLULAR DISTRIBUTION; CHOLESTEROL SYNTHESIS; CYTOSOL; ENDOCYTOSIS; ENZYME ACTIVITY; HOST CELL; HUMAN; HUMAN CELL; INFECTION PREVENTION; NONHUMAN; PRENYLATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; PROTEIN VARIANT; SEPSIS; STAPHYLOCOCCUS AUREUS;

1-PHOSPHATIDYLINOSITOL 3-KINASE; CELL LINE; CELLS, CULTURED; HUMANS; INTEGRATION HOST FACTORS; SIMVASTATIN; STAPHYLOCOCCUS AUREUS; TERPENES;

EID: 45749148199     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.108.137927     Document Type: Article

References (40)

1. Agerer F, Lux S, Michel A, Rohde M, Ohlsen K, and Hauck CR (2005) Cellular invasion by Staphylococcus aureus reveals a functional link between focal adhesion kinase and cortactin in integrin-mediated internalisation. J Cell Sci 118:2189-2200.
2. Alexander EH and Hudson MC (2001) Factors influencing the internalization of Staphylococcus aureus and impacts on the course of infections in humans. Appl Microbiol Biotechnol 56:361-366.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, and Pinsky MR (2001) Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 29:1303-1310.
4. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N, Godowski PJ, Ulevitch RJ, and Knaus UG (2000) Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol 1:533-540.
5. Bokoch GM, Vlahos CJ, Wang Y, Knaus UG, and Traynor-Kaplan AE (1996) Rac GTPase interacts specifically with phosphatidylinositol 3-kinase. Biochem J 315 (Pt 3):775-779.
6. Bondeva T, Pirola L, Bulgarelli-Leva G, Rubio I, Wetzker R, and Wymann MP (1998) Bifurcation of lipid and protein kinase signals of PI3Kgamma to the protein kinases PKB and MAPK. Science 282:293-296.
7. Brachmann SM, Yballe CM, Innocenti M, Deane JA, Fruman DA, Thomas SM, and Cantley LC (2005) Role of phosphoinositide 3-kinase regulatory isoforms in development and actin rearrangement. Mol Cell Biol 25:2593-2606.
8. Bromilow J and Schuster Bruce MJ (2007) The use of statins in intensive care unit patients with sepsis. Anaesth Intensive Care 35:256-258.
9. Clement S, Vaudaux P, Francois P, Schrenzel J, Huggler E, Kampf S, Chaponnier C, Lew D, and Lacroix JS (2005) Evidence of an intracellular reservoir in the nasal mucosa of patients with recurrent Staphylococcus aureus rhinosinusitis. J Infect Dis 192:1023-1028.
10. Cordle A, Koenigsknecht-Talboo J, Wilkinson B, Limpert A, and Landreth G (2005) Mechanisms of statin-mediated inhibition of small G-protein function. J Biol Chem 280:34202-34209.
11. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, and Beach M (2001) Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 32 (Suppl 2):S114-S132.
12. Foster TJ (2005) Immune evasion by staphylococci. Nat Rev Microbiol 3:948-958.
13. Fraley TS, Pereira CB, Tran TC, Singleton C, and Greenwood JA (2005) Phosphoinositide binding regulates alpha-actinin dynamics: mechanism for modulating cytoskeletal remodeling. J Biol Chem 280:15479-15482.
14. Goldstein JL and Brown MS (1990) Regulation of the mevalonate pathway. Nature 343:425-430.
15. Hauck CR and Ohlsen K (2006) Sticky connections: extracellular matrix protein recognition and integrin-mediated cellular invasion by Staphylococcus aureus. Curr Opin Microbiol 9:5-11.
16. Jacobson JR, Barnard JW, Grigoryev DN, Ma SF, Tuder RM, and Garcia JG (2005) Simvastatin attenuates vascular leak and inflammation in murine inflammatory lung injury. Am J Physiol Lung Cell Mol Physiol 288:L1026-L1032.
17. Johnson DI (1999) Cdc42: An essential Rho-type GTPase controlling eukaryotic cell polarity. Microbiol Mol Biol Rev 63:54-105.
18. KrügerS and Merx MW (2007) Nonuse of statins - a new risk factor for infectious death in cardiovascular patients? Crit Care Med 35:631-632.
19. Kureishi Y, Luo Z, Shiojima I, Bialik A, Fulton D, Lefer DJ, Sessa WC, and Walsh K (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6:1004-1010.
20. Kwak B, Mulhaupt F, Myit S, and Mach F (2000) Statins as a newly recognized type of immunomodulator. Nat Med 6:1399-1402.
21. Liappis AP, Kan VL, Rochester CG, and Simon GL (2001) The effect of statins on mortality in patients with bacteremia. Clin Infect Dis 33:1352-1357.
22. Lowy FD (1998) Staphylococcus aureus infections. N Engl J Med 339:520-532.
23. Mahboobi SK, Shohat EZ, Jellinek SP, and Rose M (2006) Systemic infections can decrease the threshold of statin-induced muscle injury. South Med J 99:403-404.
24. Merx MW, Liehn EA, Janssens U, Lutticken R, Schrader J, Hanrath P, and Weber C (2004) HMG-CoA reductase inhibitor simvastatin profoundly improves survival in a murine model of sepsis. Circulation 109:2560-2565.
25. Nitsche-Schmitz DP, Rohde M, and Chhatwal GS (2007) Invasion mechanisms of Gram-positive pathogenic cocci. Thromb Haemost 98:488-496.
26. Proctor RA, von Eiff C, Kahl BC, Becker K, McNamara P, Herrmann M, and Peters G (2006) Small colony variants: a pathogenic form of bacteria that facilitates persistent and recurrent infections. Nat Rev Microbiol 4:295-305.
27. Que YA, Haefliger JA, Piroth L, Francois P, Widmer E, Entenza JM, Sinha B, Herrmann M, Francioli P, Vaudaux P, et al. (2005) Fibrinogen and fibronectin binding cooperate for valve infection and invasion in Staphylococcus aureus experimental endocarditis. J Exp Med 201:1627-1635.
28. Rivas JM, Speziale P, Patti JM, and Hook M (2004) MSCRAMM-targeted vaccines and immunotherapy for staphylococcal infection. Curr Opin Drug Discov Devel 7:223-227.
29. SchröderA, Schroder B, Roppenser B, Linder S, Sinha B, Fassler R, and Aepfelbacher M (2006) Staphylococcus aureus fibronectin binding protein-A induces motile attachment sites and complex actin remodeling in living endothelial cells. Mol Biol Cell 17:5198-5210.
30. Sinha B and Herrmann M (2005) Mechanism and consequences of invasion of endothelial cells by Staphylococcus aureus. Thromb Haemost 94:266-277.
31. Stamatakis K, Cernuda-Morollon E, Hernandez-Perera O, and Perez-Sala D (2002) Isoprenylation of RhoB is necessary for its degradation. A novel determinant in the complex regulation of RhoB expression by the mevalonate pathway. J Biol Chem 277:49389-49396.
32. Tobert JA (2003) Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors. Nat Rev Drug Discov 2:517-526.
33. Vanhaesebroeck B and Waterfield MD (1999) Signaling by distinct classes of phosphoinositide 3-kinases. Exp Cell Res 253:239-254.
34. Vincent A and Miller JA (2006) Statins for sepsis: a cautionary note. Intensive Care Med 32:795.
35. Walker EH, Pacold ME, Perisic O, Stephens L, Hawkins PT, Wymann MP, and Williams RL (2000) Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol Cell 6:909-919.
36. Xu B, Pelish H, Kirchhausen T, and Hammond GB (2006) Large scale synthesis of the Cdc42 inhibitor secramine A and its inhibition of cell spreading. Org Biomol Chem 4:4149-4157.
37. Yart A, Roche S, Wetzker R, Laffargue M, Tonks N, Mayeux P, Chap H, and Raynal P (2002) A function for phosphoinositide 3-kinase beta lipid products in coupling beta gamma to Ras activation in response to lysophosphatidic acid. J Biol Chem 277:21167-21178.
38. Yeaman MR and Bayer AS (2000) Staphylococcus aureus, platelets, and the heart. Curr Infect Dis Rep 2:281-298.
39. Zhang FL and Casey PJ (1996) Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem 65:241-269.
40. Zheng Y, Bagrodia S, and Cerione RA (1994) Activation of phosphoinositide 3-kinase activity by Cdc42Hs binding to p85. J Biol Chem 269:18727-18730.